Inflammatory Bowel Disease

A presentation at the Crohn’s and Colitis Congress, highlighted recent updates on dietary therapy for inflammatory bowel disease.

Biologic therapy exposure within 60 days of inflammatory bowel disease-related surgery did not confer a risk for post-operative infectious or surgical site complications, according to research presented at the Crohn’s and Colitis Congress.

Older patients with inflammatory bowel disease who initiate Entyvio therapy had lower risk for hospitalization than those treated with anti-TNF, according to research presented at the Crohn’s and Colitis Congress.

Researchers developed a wearable sweat senser device that may improve treatment of inflammatory bowel disease, according to a presenter at the virtual Crohn’s and Colitis Congress.

Visceral fat index may indicate a patient’s risk for refractory inflammatory bowel disease and likelihood of surgery, suggesting early surgical referral in these cases, according to a presentation at the Crohn’s and Colitis Congress.

A machine learning image model describing Crohn’s disease phenotypes may impact individualized care for children with Crohn’s, according to a presenter at the Crohn’s and Colitis Congress.

A presenter at the Crohn’s and Colitis Congress highlighted the importance of biomarkers in determining disease activity in inflammatory bowel disease, especially in the era of COVID-19.

Children with inflammatory bowel disease who contract COVID-19 generally have mild disease, according to study results.

A study published in the Nature Communications concluded that a patient-derived organoid model will provide insights into pathogenesis of ulcerative colitis, which may help tailor care to the individual patient.

Patients with inflammatory bowel disease who either currently or formerly smoked cigarettes were at higher risk for colorectal neoplasia, according to study results.